![PDF] Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Semantic Scholar PDF] Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d1d9cb83bf646b3804f3f9db7a0d0bd11da925a4/2-Figure1-1.png)
PDF] Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Semantic Scholar
![Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01562-9/MediaObjects/41591_2021_1562_Fig1_HTML.png)
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine
![Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ea575e6623c8d2b583ae75e04c4cfe32d08642c7/2-Figure1-1.png)
Figure 1 from The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Semantic Scholar
![The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.jp.7211266/MediaObjects/41372_2005_Article_BF7211266_Fig1_HTML.gif)
The 4P's Plus© Screen for Substance Use in Pregnancy: Clinical Application and Outcomes | Journal of Perinatology
![Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.jp.7211823/MediaObjects/41372_2007_Article_BF7211823_Fig1_HTML.gif)
Validation of the 4P's Plus© screen for substance use in pregnancy validation of the 4P's Plus | Journal of Perinatology
![All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0a920e8d-fd31-4644-858c-66e668a32107/gr1.gif)
All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Haematology
![Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1086-y/MediaObjects/41591_2020_1086_Fig1_HTML.png)
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma | Nature Medicine
![PDF) Soil and Water Assessment Tool: Historical Development, Applications, and Future Research Directions, The PDF) Soil and Water Assessment Tool: Historical Development, Applications, and Future Research Directions, The](https://i1.rgstatic.net/publication/5103854_Soil_and_Water_Assessment_Tool_Historical_Development_Applications_and_Future_Research_Directions_The/links/5751979a08ae17e65ec3178e/largepreview.png)
PDF) Soil and Water Assessment Tool: Historical Development, Applications, and Future Research Directions, The
![Massively parallel in vivo CRISPR screening identifies RNF20/40 as epigenetic regulators of cardiomyocyte maturation | Nature Communications Massively parallel in vivo CRISPR screening identifies RNF20/40 as epigenetic regulators of cardiomyocyte maturation | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-24743-z/MediaObjects/41467_2021_24743_Fig1_HTML.png)